Literature DB >> 28815563

Bone marrow failure syndrome caused by homozygous frameshift mutation in the ERCC6L2 gene.

T Järviaho1,2,3, K Halt1,3,4, P Hirvikoski5,6, J Moilanen1,2,7, M Möttönen1,4, R Niinimäki1,4.   

Abstract

Inherited bone marrow failure syndromes (IBMFS) are group of disorders that lead to inadequate production of blood cells. Mutations in genes involved in telomere maintenance, DNA repair, and the cell cycle cause IBMFS. ERCC6L2 gene mutations have been associated with bone marrow failure that includes developmental delay and microcephaly. We report 2 cases of bone marrow failure with no extra-hematopoietic manifestations in patients from unrelated families with a homozygous truncating mutation in ERCC6L2. Bone marrow failure without developmental delay or microcephaly with ERCC6L2 mutation has not been previously described.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ERCC6L2 gene; aplastic anemia; children; inherited bone marrow failure; thrombocytopenia

Mesh:

Substances:

Year:  2017        PMID: 28815563     DOI: 10.1111/cge.13125

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  A Genetic Map of the Response to DNA Damage in Human Cells.

Authors:  Michele Olivieri; Tiffany Cho; Alejandro Álvarez-Quilón; Kejiao Li; Matthew J Schellenberg; Michal Zimmermann; Nicole Hustedt; Silvia Emma Rossi; Salomé Adam; Henrique Melo; Anne Margriet Heijink; Guillermo Sastre-Moreno; Nathalie Moatti; Rachel K Szilard; Andrea McEwan; Alexanda K Ling; Almudena Serrano-Benitez; Tajinder Ubhi; Sumin Feng; Judy Pawling; Irene Delgado-Sainz; Michael W Ferguson; James W Dennis; Grant W Brown; Felipe Cortés-Ledesma; R Scott Williams; Alberto Martin; Dongyi Xu; Daniel Durocher
Journal:  Cell       Date:  2020-07-09       Impact factor: 41.582

2.  Body Composition and Metabolic Changes in a Lyon Hypertensive Congenic Rat and Identification of Ercc6l2 as a Positional Candidate Gene.

Authors:  Karen C Clark; Valerie A Wagner; Katie L Holl; John J Reho; Monika Tutaj; Jennifer R Smith; Melinda R Dwinell; Justin L Grobe; Anne E Kwitek
Journal:  Front Genet       Date:  2022-06-24       Impact factor: 4.772

3.  Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic ERCC6L2 variants.

Authors:  Hemanth Tummala; Arran D Dokal; Amanda Walne; Alicia Ellison; Shirleny Cardoso; Saranha Amirthasigamanipillai; Michael Kirwan; Isobel Browne; Jasmin K Sidhu; Vinothini Rajeeve; Ana Rio-Machin; Ahad Al Seraihi; Andrew S Duncombe; Matthew Jenner; Owen P Smith; Helen Enright; Alice Norton; Tekin Aksu; Namık Yaşar Özbek; Nikolas Pontikos; Pedro Cutillas; Inderjeet Dokal; Tom Vulliamy
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

Review 4.  Repair of programmed DNA lesions in antibody class switch recombination: common and unique features.

Authors:  Yafang Shang; Fei-Long Meng
Journal:  Genome Instab Dis       Date:  2021-03-26

5.  Microdeletion of 9q22.3: A patient with minimal deletion size associated with a severe phenotype.

Authors:  Adam D Ewing; Seth W Cheetham; James J McGill; Michael Sharkey; Rick Walker; Jennifer A West; Malcolm J West; Kim M Summers
Journal:  Am J Med Genet A       Date:  2021-05-07       Impact factor: 2.802

Review 6.  ERCC6L2-associated inherited bone marrow failure syndrome.

Authors:  Iren Shabanova; Elisa Cohen; Michaela Cada; Ajoy Vincent; Ronald D Cohn; Yigal Dror
Journal:  Mol Genet Genomic Med       Date:  2018-04-06       Impact factor: 2.183

7.  ERCC6L2 promotes DNA orientation-specific recombination in mammalian cells.

Authors:  Xiaojing Liu; Tingting Liu; Yafang Shang; Pengfei Dai; X Shirley Liu; Fei-Long Meng; Wubing Zhang; Brian J Lee; Min Huang; Dingpeng Yang; Qiu Wu; Liu Daisy Liu; Xiaoqi Zheng; Bo O Zhou; Junchao Dong; Leng-Siew Yeap; Jiazhi Hu; Tengfei Xiao; Shan Zha; Rafael Casellas
Journal:  Cell Res       Date:  2020-04-30       Impact factor: 25.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.